Catalyst overview
Research summary
This catalyst tracks a Phase 2b data readout for KT-621 (Oral STAT6 Degrader) in Atopic dermatitis. The expected timing is based on the latest available company guidance and may change.
BROADEN2. 11/25/25- First patient dosed. Report patient trial by mid-2027. 11/04/25:- BROADEN2 Ph2b AD trial initiated; randomized design with mid-2027 primary EASI endpoint readout expected. 12/11/25:- BROADEN2 Ph2b AD trial ongoing; Fast Track granted for KT-621 in moderate-to-severe AD; data still expected mid-2027. 02/27/26:- BROADEN2 Ph2b AD trial expanded to adolescents; enrollment completes 2026; primary EASI data expected Mid-2027. 04/30/26:- BROADEN2 Ph2b AD enrollment ongoing; completion 2026; EASI primary data readout still expected mid-2027. 06/25/26:- BROADEN2 enrollment complete; topline Ph2b EASI data expected Year-End 2026. Ph3 AD initiation planned Mid-2027. 08/05/26:- BROADEN2 enrollment complete. Topline Ph2b data expected Year-End 2026. Ph3 starts Mid-2027.
Verification
Confirm timing and program details against the company announcement or filing.